Leukemia & Lymphoma Society: Transforming CURES Initiative

The overall goal is to understand the molecular hematopoietic events that mediate progression of myeloid malignancies from chronic pre-leukemic, or early stage myeloid disorders, such as myelodysplastic syndromes or myeloproliferative neoplasms, to frank hematologic malignancy that could lead to novel therapeutics to control such disease progression. Proposal topics of interest might include, but are not limited to:

• Identify the molecular, cellular and epigenetic drivers of progression to leukemia

• Identify the role of the immune system in progression from molecular alteration to full blown leukemia

• Understand the role of the microenvironment in enabling disease progression

• Develop predictive preclinical models to assess disease progression

• Develop immunologic and/or molecular monitoring approaches

• Develop treatment strategies and/or approaches for early interception (vaccines, nutraceuticals, drugs…etc.)

Funding available is for $400,000 over a period of 3 years. Each applicant to the TCI is required to have his or her Institution certify agreement with LLS’s IP terms and participation in the Transforming CURES Initiative at the time of application submission.

Guidelines: http://www.lls.org/content/nationalcontent/pdf/researchers/transforming_cures_initiative_guidelines_2014

Opportunity: http://www.lls.org/#/researchershealthcareprofessionals/academicgrants/transforming_cures_initiative/